Pemetrexed has been reported to augment intra-tumor immune responses through increased T cell infiltration/activation along with modulation of innate immune pathways and as a result, enhanced the anti-tumor activity of anti-PD-L1 in pre-clinical models45. Here, CD274 is linked to neoplasm.